Anti-IL5 therapy for severe asthma: Towards a MAB war?

被引：0
|
作者：
Le Borgne-Krams, A. [1 ]
Guilleminault, L. [2 ,3 ,4 ]
Mailhol, C. [1 ]
Didier, A. [1 ]
机构：
[1] CHU Toulouse, Hop Larrey, Pole Voies Resp, 24 Chemin Pouvourville, F-31059 Toulouse 9, France
[2] CHU Reunion, GHSR, Pneumol, BP 350, F-97448 St Pierre, Reunion, France
[3] INSERM, Plateforme CYROI, UMR 1188, Diabet Atherothrombose Therapies Reunion Ocean In, F-97490 St Clotilde, Reunion, France
[4] Univ La Reunion, UMR 1188, F-97490 St Clotilde, Reunion, France
来源：
REVUE FRANCAISE D ALLERGOLOGIE | 2016年 / 56卷 / 7-8期
关键词：
Asthma; Eosinophil; IL-5; Biotherapies; Benralizumab; Mepolizumab; Reslizumab; SEVERE EOSINOPHILIC ASTHMA; ALPHA MONOCLONAL-ANTIBODY; DOUBLE-BLIND; BENRALIZUMAB; MEPOLIZUMAB; PLACEBO; ANTI-INTERLEUKIN-5; INTERLEUKIN-5; RESLIZUMAB; ADULTS;
D O I：
10.1016/j.reval.2016.08.003
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
The presence of eosinophilic inflammation is the most frequent clinical phenotype encountered in patients with severe asthma. Interleukin-5 (IL-5) is a pro-inflammatory cytoldne that plays a pivotal pathogenic role in eosinophilic asthma; it is involved in eosinophil differentiation, activation and tissue migration, and it is equally involved in eosinophil survival and the prevention of apoptosis. Several monoclonal antibodies (MABs) targeting IL-5 or its cellular receptor are currently being developed for the treatment of severe asthma. We discuss their mode of action and the results observed in recently published clinical trials. It seems that, generally, anti-IL-5 therapies have as their target a reduction of the frequency of asthma exacerbations and improvement of clinical and lung function parameters in selected patients with severe asthma and an eosinophilic phenotype. This new therapeutic class of drugs should certainly lead to improvement in the management of patients with persistent severe eosinophilic asthma who have not responded to currently available anti-asthmatic treatment. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：549 / 555
页数：7
相关论文
共 50 条
  • [41] Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy.
    Panagiotou, Marios
    Koutsoukou, Antonia
    Koulouris, Nikolaos
    Rovina, Nikoletta
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [42] The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma
    Bergantini, Laura
    Pianigiani, Tommaso
    d'Alessandro, Miriana
    Gangi, Sara
    Cekorja, Behar
    Bargagli, Elena
    Cameli, Paolo
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 166
  • [43] Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
    Laorden Escudero, Daniel
    Zamarron De Lucas, Ester
    Romero Ribate, David
    Fernandez Lahera, Juan
    Garcia Rio, Francisco
    Villasante Fernandez, Carlos
    Alvarez-Sala Walther, Rodolfo
    Quirce Gancedo, Santiago
    Padilla Brito, Jose Manuel
    Barranco Sanz, Pilar
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [44] Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma
    Jang, Jae-Hyuk
    Woo, Seong-Dae
    Lee, Youngsoo
    Kim, Chang-Keun
    Shin, Yoo Seob
    Ye, Young-Min
    Park, Hae-Sim
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2021, 13 (02) : 330 - 338
  • [45] Mepolizumab (Anti-IL5) and Exacerbation Frequency in Refractory Eosinophilic Asthma
    Haldar, P.
    Brightling, C.
    Hargadon, B.
    Gupta, S.
    Monteiro, W.
    Sousa, A.
    Marshall, R.
    Bradding, P.
    Green, R.
    Wardlaw, A.
    Pavord, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [46] THE RELATIONSHIP BETWEEN FENO AND RESPONSE TO ANTI-IL5/5R BIOLOGIC THERAPIES IN SEVERE EOSINOPHILIC ASTHMA
    Hearn, A. P.
    Kavanagh, J.
    d'Ancona, G.
    Fernandes, M.
    Green, L.
    Roxas, C.
    Thomson, L.
    Dhariwal, J.
    Nanzer, A. M.
    Jackson, D. J.
    THORAX, 2021, 76 : A143 - A144
  • [47] Worldwide Characterization of Severe Asthma Patients Eligible for Both Anti-IL5 and Anti-IgE: Data from the International Severe Asthma Registry (ISAR)
    Sadatsafavi, M.
    Murray, R.
    Ali, N.
    Trung, T.
    Price, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [48] Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both
    Pfeffer, Paul E.
    Ali, Nasloon
    Murray, Ruth
    Ulrik., Charlotte
    Tran, Trung N.
    Maspero, Jorge
    Peters, Matthew
    Christoff, George C.
    Sadatsafavi, Mohsen
    Torres-Duque, Carlos A.
    Altraja, Alan
    Lehtimaki, Lauri
    Papadopoulos, Nikolaos G.
    Salvi, Sundeep
    Costello, Richard W.
    Cushen, Breda
    Heffler, Enrico
    Iwanaga, Takashi
    Al-Ahmad, Mona
    Larenas-Linnemann, Desiree
    Kuna, Piotr
    Fonseca, Joao A.
    Al-Lehebi, Riyad
    Rhee, Chin Kook
    Perez-de-Llano, Luis
    Perng Steve, Diahn-Warng
    Mahboub, Bassam
    Wang, Eileen
    Goh, Celine
    Lyu, Juntao
    Newell, Anthony
    Alacqua, Marianna
    Belevskiy, Andrey S.
    Bhutani, Mohit
    Bjermer, Leif
    Bjornsdottir, Unnur
    Bourdin, Arnaud
    von Boulow, Anna
    Busby, John
    Canonica, Giorgio Walter
    Cosio, Borja G.
    Dorscheid, Delbert R.
    Munoz-Esquerre, Mariana
    FitzGerald, J. Mark
    Gil, Esther Garcia
    Gibson, Peter G.
    Heaney, Liam G.
    Hew, Mark
    Hilberg, Ole
    Hoyte, Flavia
    ALLERGY, 2023, 78 (07) : 1934 - 1948
  • [49] Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
    Burkill, S.
    Porsbjerg, C. M.
    Bourdin, A.
    Tran, T. N.
    Martin, N.
    Katial, R.
    Barker, P.
    Wechsler, M. E.
    Maspero, J.
    Bosnic-Anticevich, S.
    Chung, L. P.
    Katsoulotos, G.
    Christoff, G. C.
    Popov, T. A.
    Sadatsafavi, M.
    Torres-Duque, C. A.
    Ulrik, C.
    Assing, K. Dahl
    Hansen, S.
    Altraja, A.
    Lehtimaki, L. A.
    Papadopoulos, N. G.
    Kostikas, K.
    Salvi, S.
    Costello, R. W.
    Francesca, P.
    Iwanaga, T.
    Rhee, C. K.
    Al-Ahmad, M.
    Larenas-Linnemann, D.
    Fonseca, J. A.
    Amaral, R.
    Alving, K.
    Al-Lehebi, R.
    De-Llano, L. Perez
    Kirenga, B.
    Tsai, M.
    Mahboub, B.
    Pfeffer, P. E.
    Henley, W.
    Liu, Y.
    Lyu, J.
    Goh, C.
    Uthaman, T.
    Price, D.
    Townend, J.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [50] DEVELOPMENT OF A DEDICATED PROTOCOL FOR SCREENING FOR OCCULT PARASITIC INFECTION PRIOR TO INITIATION OF ANTI-IL5 THERAPY IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA
    Cushen, B.
    Stead, R.
    Malley, S.
    Armstrong-James, D.
    Hull, J.
    THORAX, 2019, 74 : A36 - A36
12345